Cindy Leissinger

Tulane University — United States

Medicine · Health Sciences

34h-index6.4kcitations163works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemophilia Treatment and Research(113), Platelet Disorders and Treatments(62), Blood Coagulation and Thrombosis Mechanisms(31), Coagulation, Bradykinin, Polyphosphates, and Angioedema(24), Myeloproliferative Neoplasms: Diagnosis and Treatment(18)

Publications162 total

Efficacy and Safety of rVIII‐SingleChain in Surgical Prophylaxis
Haemophilia·2025· 2 citedOpen Access
Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk
Journal of Thrombosis and Haemostasis·2024· 1 cited
Bleeding control with emicizumab in patients with acquired hemophilia a
The American Journal of the Medical Sciences·2024
An in Vitro Pilot Study of the Role of Factor IX As an Alternative to Bypassing Agents in the Treatment of Breakthrough Bleeds in Patients with Hemophilia a and Inhibitors Treated with Emicizumab
Blood·2023
Another Victory for Patients with Hemophilia
New England Journal of Medicine·2023· 3 cited
Ristocetin dependent cofactor activity in von Willebrand disease diagnosis: Limitations of relying on a single measure
Research and Practice in Thrombosis and Haemostasis·2022· 12 citedOpen Access
Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
Journal of the Advanced Practitioner in Oncology·2022· 3 citedOpen Access
Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program
Journal of Thrombosis and Haemostasis·2022· 20 citedOpen Access
IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data
Journal of Clinical Medicine·2022· 13 citedOpen Access
PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol
Blood·2021· 1 cited
Cover Image
Haemophilia·2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
Haemophilia·2021· 13 citedOpen Access
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
Haemophilia·2021· 12 citedOpen Access
B cell–activating factor modulates the factor VIII immune response in hemophilia A
Journal of Clinical Investigation·2021· 26 citedOpen Access
Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage
UNC Libraries·2020Open Access
Rituximab for treatment of inhibitors in haemophilia A: A Phase II Study
UNC Libraries·2020· 4 citedOpen Access
Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices
Blood·2020
PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors
Blood·2020
Laboratory variability in the diagnosis of type 2 VWD variants
Journal of Thrombosis and Haemostasis·2020· 20 citedOpen Access
Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study
Journal of Thrombosis and Haemostasis·2019· 12 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Thomas C. Abshire(12), Amy D. Shapiro(11), W. Keith Hoots(10), Joan Cox Gill(10), Margaret V. Ragni(9), Steven R. Lentz(8), Marilyn J. Manco‐Johnson(7), Leonard A. Valentino(7), Donna DiMichele(7), Jeanne M. Lusher(7), Barbara A. Konkle(6), Rebecca Kruse‐Jarres(6), Veronica H. Flood(6), Pamela A. Christopherson(6), Sandra L. Haberichter(6), Robert R. Montgomery(6), M. Elaine Eyster(6), Amy L. Dunn(6), Deborah Brown(5), Christine L. Kempton(5)